Free Trial
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Aerovate Therapeutics logo
$7.49 +0.17 (+2.32%)
As of 08/8/2025

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Key Stats

Today's Range
$7.12
$7.58
50-Day Range
$6.76
$11.14
52-Week Range
$56.35
$105.00
Volume
77,779 shs
Average Volume
12,438 shs
Market Capitalization
$217.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTE Stock News Headlines

Aerovate Therapeutics (AVTE) Projected to Post Earnings on Monday
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Headlines

AVTE Stock Analysis - Frequently Asked Questions

Aerovate Therapeutics' stock was trading at $92.75 at the beginning of the year. Since then, AVTE stock has decreased by 91.9% and is now trading at $7.49.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings data on Friday, April, 25th. The company reported ($3.15) EPS for the quarter, topping the consensus estimate of ($10.50) by $7.35.

Shares of Aerovate Therapeutics reverse split on the morning of Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
4/25/2025
Today
8/10/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVTE
CIK
1798749
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-90.19%
Return on Assets
-77.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.78
Quick Ratio
8.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.96 per share
Price / Book
1.89

Miscellaneous

Outstanding Shares
28,985,000
Free Float
21,685,000
Market Cap
$217.10 million
Optionable
Optionable
Beta
0.95
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:AVTE) was last updated on 8/11/2025 by MarketBeat.com Staff
From Our Partners